Beclomethasone dipropionate for the treatment of ulcerative colitis

Bibliography

• Cosnes J, Gower–Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2012;365:1713-25
   Google Scholar
• Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: current management. J Crohns Colitis 2012;6:991-1030
   PubMed Web of Science ®Google Scholar
• Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011;106(Suppl 1):S2-25
   PubMed Web of Science ®Google Scholar
• Hoes NJ, Jacobs JW, Verstappen SM, et al. Adverse events of low-to-medium dose oral glucocorticoids in inflammatory disease: a meta-analysis. Ann Rheum Dis 2009;68:1833-9
   PubMed Web of Science ®Google Scholar
• Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60
   PubMed Web of Science ®Google Scholar
• Scholmerich J. Review article: systemic and topical steroids in inflammatory bowel disease. Aliment Pharmacol Ther 2004;20(Suppl 4):66-74
   Google Scholar
• Wurthwein G, Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990;11:381-94
   PubMed Web of Science ®Google Scholar
• Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994;59:597-602
   PubMedGoogle Scholar
• Rohdewald P, Von Eiff N. Activation of beclomethasone dipropionate in bronchial secretion and receptor affinities and solubility oh ihnalationally administered glucocorticoids. Atemwegs und Lungenkrankh 1990;16:79-84
   Google Scholar
• Brogden RN, Heel RC, Speight TM. Beclomethasone dipropionate: a reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. Drugs 1984;28:99-126
   PubMed Web of Science ®Google Scholar
• Prantera C. Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity. Ther Adv Gastroenterol 2013;6(2):137-56
   Google Scholar
• Steed KP, Hooper G. The in vivo behaviour of a colonic delivery system. Pharmaceutical Profiles Limited study no. Int J Pharm 1994;112:199-206
   Web of Science ®Google Scholar
• Campieri M, Cottone M, Miglio F, et al. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther 1998;12:361-6
   PubMed Web of Science ®Google Scholar
• Bansky G, Buhler H, Stamm B, et al. Treatment of distal ulcerative colitis with beclomethasone enemas: high therapeutic efficacy without endocrine side effects. A prospective, randomized, double-blind trial. Dis Colon Rectum 1987;30:288-92
   PubMed Web of Science ®Google Scholar
• Halpern Z, Sold O, Baratz M, et al. A controlled trial of beclomethasone versus betamethasone enemas in distal ulcerative colitis. J Clin Gastroenterol 1991;13:38-41
   PubMed Web of Science ®Google Scholar
• Gionchetti P, D’Arienzo A, Rizzello F, et al.The Italian BDP. Study Group. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine. A single-blind randomized controlled trial. J Clin Gastroenterol 2005;39:291-7
   PubMed Web of Science ®Google Scholar
• Biancone L, Gionchetti P, Blanco Gdel V, et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis 2007;39:329-37
   PubMedGoogle Scholar
• Franze A, Galeazzi R, Marcucci F, et al. Topical treatment of ulcerative colitis. Double blind study between beclomethasone dipropionate and mesalazine. Minerva Gastroenterol Dietol 1999;45:287-96
   Google Scholar
• Mulder CJ, Fockens P, Meijer JV, et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;8:549-53
   PubMed Web of Science ®Google Scholar
• Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther 2007;26:21-9
   PubMed Web of Science ®Google Scholar
• Lemann M, Galian A, Rutgeers P, et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:557-62
   PubMed Web of Science ®Google Scholar
• Rufle W, Fruhmorgen P, Huber W, et al. [Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study]. Z Gastroenterol 2000;38:287-93
   Google Scholar
• Lamers C, Meijer J. Comparative study of the topically acting glucocorticosteroid budesonide and 5-aminosalicylic acid enema therapy of proctitis and proctosigmoiditis. Gastroenterology 1991;100:A223
   Google Scholar
• Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010(1):CD004115
   Google Scholar
• Fascì Spurio F, Aratari A, Margagnoni G, et al. Oral Beclomethasone Dipropionate: a Critical Review of its Use in the Management of Ulcerative Colitis and Crohn’s Disease. Curr Clin Pharmacol 2012;7:2
   Google Scholar
• Rizzello F, Gionchetti P, D’Arienzo A, et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002;16:1109-16
   PubMed Web of Science ®Google Scholar
• Campieri M, Adamo S, Valpiani D, et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 2003;17:1471-80
   PubMed Web of Science ®Google Scholar
• Romano C, Famiani A, Comito D, et al. Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine. J Pediatr Gastroenterol Nutr 2010;50:385-9
   PubMedGoogle Scholar
• Rizzello F, Gionchetti P, Galeazzi R, et al. Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study. Adv Ther 2001;18:261-71
   PubMed Web of Science ®Google Scholar
• Papi C, Aratari A, Moretti A, et al. Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci 2010;55:2002-7
   PubMed Web of Science ®Google Scholar
• Balzano A, Manguaso F, Alberici M, et al. Efficacy and safety of beclomethasone dipropionate gastro-resistant, prolonged release tablet in mild to moderate ulcerative colitis: the Beta study. J Crohns Colitis 2010;4(1):S53
   Google Scholar
• Gionchetti P, Calabrese C, Calafiore A, et al. Oral beclomethasone dipropionate in chronic refractory pouchitis. J Crohn Colitis 2014;8(7):649-53
   Google Scholar
• Nunes T, Barreiro-de Acosta M, Nos P, et al. Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study. J Crohns Colitis 2010;4:629-36
   PubMed Web of Science ®Google Scholar